NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00310-4500-12 | 00310-4500 | Durvalumab | Imfinzi | 120.0 mg/2.4mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | May 1, 2017 | In Use | |
63304-0046-22 | 63304-0046 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
55513-0206-01 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
50242-0070-86 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 4, 2013 | In Use | |
00004-0357-99 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Aug 22, 2011 | Sep 19, 2014 | No Longer Used |
45802-0076-62 | 45802-0076 | Imiquimod | Imiquimod | 50.0 mg/1000mg | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Apr 20, 2010 | Aug 1, 2013 | No Longer Used |
50242-0917-86 | 50242-0917 | Atezolizumab | Tecentriq | 1200.0 mg/20mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Aug 11, 2016 | In Use | |
45802-0368-62 | 45802-0368 | Imiquimod | Imiquimod | 12.5 mg/.25g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Nov 9, 2010 | In Use | |
57894-0450-01 | 57894-0450 | Teclistamab | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
83257-0003-01 | 83257-0003 | Trastuzumab-dkst, Trastuzumab | OGIVRI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
71287-0219-02 | 71287-0219 | brexucabtagene autoleucel | TECARTUS | 2000000.0 1/68mL | Immunotherapy | CAR-T | CD19 | Intravenous | Jul 24, 2020 | In Use | |
70771-1680-01 | 70771-1680 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
00093-6126-64 | 00093-6126 | Imiquimod | Imiquimod | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Dec 19, 2013 | Apr 30, 2015 | No Longer Used | |
50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
55513-0132-01 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 11, 2019 | In Use | |
70377-0051-13 | 70377-0051 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
59572-0402-28 | 59572-0402 | Lenalidomide | Revlimid | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 9, 2012 | In Use | |
73380-4700-01 | 73380-4700 | MOXETUMOMAB PASUDOTOX | LUMOXITI | 1.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | May 15, 2020 | In Use | |
55513-0207-01 | 55513-0207 | Bevacizumab-awwb | MVASI | 400.0 mg/16mL, 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
70121-1754-07 | 70121-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use | |
00004-0350-09 | 00004-0350 | Peginterferon alfa-2a | Pegasys | 180.0 ug/mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Oct 16, 2002 | Jun 30, 2025 | In Use |
59572-0425-21 | 59572-0425 | Lenalidomide | Revlimid | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2009 | In Use | |
50881-0006-03 | 50881-0006 | Retifanlimab-dlwr | ZYNYZ | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 22, 2023 | In Use | |
70771-1680-08 | 70771-1680 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
47781-0485-01 | 47781-0485 | Lenalidomide | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 3, 2022 | In Use |
Found 11564 results — Export these results